Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Company Drug

Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study

Fineline Cube Mar 26, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved...

Company Deals

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access

Fineline Cube Mar 26, 2025

China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical...

Company

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline

Fineline Cube Mar 26, 2025

China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...

Company Deals

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346

Fineline Cube Mar 26, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck...

Company Drug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Fineline Cube Mar 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061

Fineline Cube Mar 26, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Deals

Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions

Fineline Cube Mar 26, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with molecular diagnostics specialist Sansure...

Company Drug

AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China

Fineline Cube Mar 25, 2025

UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its...

Company Deals Drug

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fineline Cube Mar 25, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...

Company Deals

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields

Fineline Cube Mar 25, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with Tencent Healthcare, the healthcare...

Company Drug

Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial

Fineline Cube Mar 25, 2025

Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...

Company Drug

Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial

Fineline Cube Mar 25, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial

Fineline Cube Mar 25, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...

Company

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement

Fineline Cube Mar 25, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced receiving a one-month prior written notice dated March...

Company

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift

Fineline Cube Mar 25, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...

Company

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales

Fineline Cube Mar 25, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...

Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Drug Medical Device Policy / Regulatory

China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement

Fineline Cube Mar 25, 2025

China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...

Company Medical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Fineline Cube Mar 25, 2025

Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...

Company Drug

SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study

Fineline Cube Mar 25, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...

Posts pagination

1 … 126 127 128 … 602

Recent updates

  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.